Ilinpru

Linagliptin, the active ingredient in Ilinpru, is a dipeptidyl peptidase-4 (DPP‑4) inhibitor presented as a tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients.

GNH USA supplies Ilinpru as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ilinpru, a DPP‑4 inhibitor, is used in the treatment pathway of type 2 diabetes mellitus.

- Type 2 diabetes mellitus: improves glycaemic control when combined with diet and exercise. - Adjunct therapy: used alongside metformin or other antidiabetic agents to achieve target HbA1c. - Monotherapy: can be prescribed as initial therapy for patients inadequately controlled by lifestyle alone.

Common and serious adverse reactions have been reported with linagliptin therapy.

Common Side Effects: - Nasopharyngitis: mild inflammation of the nose and throat. - Headache: transient cranial pain. - Upper respiratory tract infection: symptoms of cough and congestion. - Urinary tract infection: dysuria or frequency. - Dizziness: sensation of light‑headedness. - Back pain: musculoskeletal discomfort.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain with elevated enzymes. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Hepatic injury: jaundice or abnormal liver tests. - Bullous pemphigoid: blistering skin disorder. - Hypersensitivity reactions: fever, eosinophilia, or organ involvement.

When prescribing Ilinpru, clinicians should consider several precautionary measures.

- Renal impairment: dose adjustment is not required, but monitor renal function regularly. - Hepatic impairment: use with caution in patients with moderate liver disease. - Cardiovascular disease: assess risk as patients may have existing heart conditions. - Elderly patients: monitor for dehydration and orthostatic hypotension. - Pregnancy and lactation: safety not established; avoid unless benefit outweighs risk. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in original packaging.

Linagliptin may interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Other DPP‑4 inhibitors: concurrent use can increase risk of adverse effects. - Strong P‑glycoprotein inhibitors (e.g., ketoconazole, itraconazole): may raise linagliptin plasma levels. - Strong P‑glycoprotein inducers (e.g., rifampin): may reduce linagliptin exposure.

Moderate Interactions (Monitor Closely): - Insulin or sulfonylureas: increased risk of hypoglycaemia, adjust dose as needed. - Diuretics: monitor renal function and electrolytes. - NSAIDs: may affect renal function, especially in dehydrated patients.